Waters Earnings Call Transcripts
Fiscal Year 2026
-
Integration of the BD acquisition is progressing, with a focus on operational precision and cross-team learning. Financial guidance is conservative due to China headwinds, but margin and EPS targets are maintained. Core business growth is supported by strong recurring revenues and new product innovation.
-
A five-year transformation drove commercial and innovation gains, expanding into high-growth adjacencies and culminating in the acquisition of BD's Bioscience and Diagnostics business. The integration is expected to deliver significant cost and revenue synergies, with a strong financial outlook and continued leadership in innovation and growth.
Fiscal Year 2025
-
Delivered strong Q4 and full-year growth, completed BD acquisition, and set 2026 guidance for 5.3% blended revenue growth and 8.9–10.4% adjusted EPS growth. Integration and synergy initiatives are underway, with robust momentum in pharma, chemistry, and recurring revenue.
-
Instrument replacement cycles and innovation in bioseparations, informatics, and diagnostics are driving strong growth, with new products and software models expanding market share. Integration of BD is on track, and forward-looking initiatives are expected to sustain higher growth rates.
-
Q3 sales and earnings exceeded guidance, with 8% revenue growth and 16% adjusted EPS growth. Pharma and Chemistry segments led performance, and the outlook for 2025 and 2026 remains strong, supported by innovation, new product launches, and the pending BD combination.
-
Strong growth in instrumentation and new products, robust replacement cycle, and double-digit China recovery were highlighted. The BD acquisition is expected to deliver significant cost and revenue synergies, with integration focused on operational discipline and cultural alignment.
-
Q2 sales and EPS exceeded guidance, driven by strong pharma and recurring revenue growth. Full-year 2025 sales and EPS guidance were raised, with robust demand in pharma, CDMOs, and China. The pending BD combination is expected to deliver significant synergies and long-term growth.
-
Waters will acquire BD's Biosciences and Diagnostic Solutions business via a $17.5B Reverse Morris Trust, issuing 39.2% of shares to BD shareholders and assuming $4B in debt. The combined company expects $6.5B revenue in 2025, $490M in synergies by year five, and aims for 32% margins by 2030, creating a leader in regulated, high-volume scientific workflows.
-
Significant innovation was highlighted, including new HPLC and mass spec products, expanded software capabilities, and strong growth in key markets like India. Regulatory changes are boosting demand for sensitive detection, while digital transformation and targeted M&A support long-term strategy.
-
Q1 2025 saw strong sales and double-digit instrument growth, with robust demand in pharma and industrial markets. Guidance for full-year sales and EPS was raised, with tariff impacts largely mitigated and continued momentum expected across key segments.
-
High single-digit growth is driven by replacement cycles, biologics, generics, and PFAS testing, with pricing power supported by differentiated chemistry and service. Innovation in software and hardware, along with a cautious approach in China, underpins a robust outlook.
-
Management outlined a new era of high single-digit growth, driven by expansion into high-growth adjacencies, robust pricing, and operational excellence. Strategic investments in innovation, recurring revenue, and targeted M&A are expected to elevate margins and EPS growth, with disciplined capital deployment and a focus on execution.
-
A disciplined transformation plan has driven strong growth, margin expansion, and resilience, with recurring revenue and innovation fueling performance. New adjacencies and pent-up demand set the stage for above-average growth in 2025, supported by robust operational execution.
Fiscal Year 2024
-
Q4 2024 saw strong revenue and EPS growth, led by pharma and new product launches, with robust performance across all regions. 2025 guidance anticipates 4.5%-7% constant currency sales growth and 7%-10% EPS growth, despite FX headwinds. Free cash flow enabled significant debt reduction and supports future M&A and share repurchases.
-
Q3 delivered broad-based growth, with instruments rebounding and recurring revenues stable. China is stabilizing with stimulus-driven upside expected in 2025, while India continues rapid expansion. Efficiency initiatives and new product launches support margin expansion, with GLP-1s, PFAS, and battery testing as key growth drivers.
-
Q3 delivered strong revenue, margin, and EPS growth, with positive trends across all regions and end markets. Guidance for Q4 and full-year 2024 was raised, reflecting improved customer spending, robust recurring revenue, and continued margin expansion.
-
Q2 results exceeded expectations with strong operational execution, though sales declined 4% year-over-year. Guidance for 2024 was revised downward to reflect a more gradual recovery, but margin performance remains resilient and new product launches and the Wyatt acquisition support long-term growth.
-
Instrument and consumables growth remains robust, especially in China, with strong indicators from service and chemistry revenues. Innovation in large molecules, informatics, and environmental testing is driving new opportunities, while efficiency initiatives and disciplined capital allocation support margin expansion and future M&A.